ArticleOncotarget2015

Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.

Yozo Mitsui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.